Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 5,585 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 5,585 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.49, for a total transaction of $19,491.65. Following the completion of the sale, the chief executive officer now owns 3,039,194 shares in the company, valued at $10,606,787.06. The trade was a 0.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Organogenesis Stock Performance

NASDAQ:ORGO opened at $3.55 on Tuesday. Organogenesis Holdings Inc. has a 12 month low of $2.16 and a 12 month high of $4.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a market capitalization of $470.66 million, a PE ratio of -59.17 and a beta of 1.73. The business’s fifty day moving average price is $3.43 and its 200 day moving average price is $3.00.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the prior year, the business posted $0.02 EPS. On average, sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORGO. Captrust Financial Advisors acquired a new position in shares of Organogenesis in the 3rd quarter valued at $36,000. Pallas Capital Advisors LLC acquired a new position in Organogenesis in the second quarter valued at $38,000. Delap Wealth Advisory LLC acquired a new position in Organogenesis in the second quarter valued at $40,000. Intech Investment Management LLC purchased a new position in shares of Organogenesis during the third quarter worth about $43,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after purchasing an additional 15,369 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.